The global companion
diagnostics market will be valued at $5.6 billion in 2019. It is
expected to grow at a CAGR of 18.1% from 2013 to 2019, and was valued
at $1.8 billion in 2013, according to a research report published by
Transparency Market Research.
The research report,
titled “Companion
Diagnostics Market - Global Industry Analysis, Size, Share, Growth,
Trends and Forecast, 2013 - 2019”, fully explores
current and future possibilities in the growing segment of companion
diagnostics.
The report states
that the companion diagnostics market for breast cancer was the
dominant sector in 2012, in terms of revenue. The upcoming sector for
the near future is lung cancer. The segment is growing at a CAGR of
more than 20% between 2013 and 2019. The report cites reasons for
growth as the discovery of lung cancer specific biomarkers, along
with a myriad of relevant companion diagnostics.
Browse The Market
Research Report of Companion
Diagnostics Market :
The largest market
according to region in 2012 was North America, with the E.U. in
following. The report said that the factors that favored the market’s
growth were positive healthcare policies, a growing consumer base,
increasing disposable incomes, improvements in healthcare systems,
and increased awareness. The acceptance of modern medicine into
mainstream sectors in the U.S. and the E.U. are the prime reasons for
the growth of this market. The Asia-Pacific region and the Rest of
the World regions are set to show considerable growth by the year
2019. The report cites untapped potential, increasing disposable
incomes, and an improving healthcare infrastructure.
The report explains
that companion diagnostics are tests which assist physicians while
making decisions regarding the most efficient treatment methods,
depending on responses by the patient over ongoing treatment.
Get Free
Sample Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=387
Key restraints as
explained by the report include regulatory restrictions,
commercialization of companion diagnostics, heavy procedure costs,
long phases of approval, and lack of reach towards the low income
countries.
Key companies in the
companion diagnostics market include Quagen N.V., Abbott
Laboratories, Life Technologies, Genomic Health, Inc., GE Healthcare
Ltd., Roche Holdings AG, Agilent Technologies, Inc., and Agendia N.V.
The report provides
exhaustive details on the companion diagnostics market by segmenting
it according to indications and geography. By indications, the market
is classified into breast cancer, lung cancer, melanoma, gastric
cancer, colorectal cancer, and others such as HIV and thalassemia.
According to geography, the reports details North America, Europe,
Asia-Pacific, and Rest of the World.
Browse Press
Release of Companion
Diagnostics Market :
About Us :
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. We are privileged with
highly experienced team of Analysts, Researchers, and Consultants,
who use proprietary data sources and various tools and techniques to
gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
No comments:
Post a Comment